Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

A study led by TUM researchers finds that cystic fibrosis alters immune cells early in life, likely before birth. These ...

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...

Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...

Sionna Therapeutics, Inc SION IPO will take place February, 07 on the NASDAQ exchange under the ticker SION. The company is ...

Cystic-fibrosis-focused Sionna Therapeutics made its public debut this week, with an upsized public offering. Meanwhile, Titan America had a ...

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause of bacterial pneumonia for them. Indeed, it was the most frequently isolated ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical ...